These novel findings expand the scope of the adverse health outcomes that have been associated with these products,” the researchers wrote.

Treatment with guselkumab led to improvements in disease activity over 1 year among patients with PsA and showed a high retention rate.

Human papillomavirus vaccination reached 82.1% by 2023, lowering rates among both unvaccinated and vaccinated individuals.

The unadjusted rates of clinical practice attrition among physicians increased from 3.5% in 2013 to 4.9% in 2019.

Early apremilast initiation is associated with reduced psoriasis activity and burden compared with late initiation or continued topical therapy use.